The Company was able to export naturally derived psilocybin to their California-based Supply Partner, Mycrodose Therapeutics late last week. VANCOUVER, BC, Dec. 13, 2021 /CNW/ – Havn Life Sciences Inc.(CSE: HAVN) (OTC: HAVLF) (FSE: 5NP)(the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential active…


Previous articleCOMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
Next articleMINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer